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Summary [1311]meta-iodobenzylguanidine ([1311]MIBG) provides a means of selectively delivering radiation to neuroblastoma cells and is a
promising addition to the range of agents used to treat neuroblastoma. As MIBG is now being incorporated into multimodal approaches to
therapy, important questions arise about the appropriate scheduling and sequencing of the various agents employed. As the ability of
neuroblastoma cells to actively accumulate MIBG is crucial to the success of this therapy, the effect of chemotherapeutic agents on this
uptake capacity needs to be investigated. We report here our initial findings on the effect of cisplatin pretreatment on the neuroblastoma cell
line SK-N-BE (2c). After treating these cells with therapeutically relevant concentrations of cisplatin (2 giM and 20 IgM), a stimulation in uptake
of [1311]MIBG was observed. Reverse transcription-polymerase chain reaction (RT-PCR) analysis demonstrated that this effect was due to
increased expression of the noradrenaline transporter. These results suggest that appropriate scheduling of cisplatin and [1311]MIBG may lead
to an increase in tumour uptake of this radiopharmaceutical with consequent increases in radiation dose to the tumour.
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Although ['311I]MIBG has single-agent efficacy, the use of this
radiopharmaceutical alone is unlikely to be curative for the
majority of neuroblastoma patients with advanced-stage disease.
Therefore, in many treatment centres, MIBG is now often used in
combination with more conventional therapies (De Kraker et al,
1995; Gaze et al, 1995; Mastrangelo et al, 1995; Voute et al, 1995).
In the UK, a multicentre study of ['311]MIBG as primary agent
followed by multiagent chemotherapy has recently commenced
(Gaze and Wheldon 1996). Accordingly, it is important to establish
the optimal scheduling of different treatment modalities. On
theoretical grounds, maximal benefit should be obtained when
[131I]MIBG administration precedes combination chemotherapy
(Gaze and Wheldon, 1996). This is because chemotherapy-induced
tumour regression could lead to reduced MIBG uptake in dead or
dying cells resulting in less killing of surviving cells by radiation
cross-fire. However, the effect ofprior exposure of tumour cells to
cytotoxic drugs upon MIBG accumulation has yet to be defined.
Nonetheless, it is known that the administration of therapeutic
agents can modulate the ability ofcultured neuroblastoma cells to
transport MIBG. For example, Smets et al (1991) have shown that
5 Gy external beam irradiation stimulated MIBG uptake by
neuroblastoma cells in vitro. The effect may have been due to the
selective depletion of proliferating cells, suggesting that the more
differentiated component ofthe culture had greatercapacity forthe
active uptake of MIBG. This hypothesis was supported by the
observation of a twofold enhancement of the uptake of MIBG by
neuroblastoma cells after 3 days exposure to interferon-gamma
which induced morphological changes indicative ofa more mature
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phenotype (Montaldo et al, 1992). This was accompanied by
increased transcription of the noradrenaline transporter gene,
suggesting that differentiation-inducing agents, which up-regulate
the expression of neuronal-specific genes, could be used in
conjunction with MIBG in neuroblastoma patients to enhance the
uptake by tumours ofthe radiopharmaceutical.
The efficacy of cisplatin administration in combination with
['311]MIBG is undergoing clinical evaluation (Mastrangelo et al,
1995). Therefore, we have studied the influence ofcisplatin prein-
cubation on the uptake and retention of MIBG and on the expres-
sion ofthe noradrenaline transporter gene by neuroblastoma cells.
MATERIALS AND METHODS
Cell lines
The human neuroblastoma cell line SK-N-BE (2c) was used for
these studies. This cell line was derived from the bone marrow ofa
patient with progressive neuroblastoma following treatment with
radiotherapy and chemotherapy (Beidler et al, 1978), and it has a
high capacity for uptake ofMIBG (Mairs et al, 1994).
Culture conditions
Cells were grown in a 5% carbon dioxide atmosphere at 37°C in
RPMI-1640 medium supplemented with 10% fetal calf serum,
penicillin/streptomycin (100 IU ml-'), amphotericin B (2 mg ml-')
and glutamine (200 mM). All media and supplements were
obtained from Gibco (Paisley, UK).
Reagents
['3'I]MIBG with a specific activity of 45-65 MBq mg-' was
obtained from Dupont Radiopharmaceuticals (Hertfordshire, UK).
470Cisplatin modulation ofMIBG uptake 471
12
11
10
CLco
o 8
m x
6
5
4
0.0 0.2 0.4 0.6
Culture density
(cell no. x 105cm2)
Figure 1 Effect of culture density on MIBG uptake in SK-I
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Table 1 Effect of culture density on noradrenaline transpo
SK-N-BE(2c) cells.
R T Culture density I
(cell no. x 105 cm4)
0.09
0.16
0.19
0.37
0.65
0.86
Target to reference ratios were calculated from the intensil
measured by scanning of ethidium bromide-stained gels. F
sequence (GAPDH); T, target sequence (noradrenaline tra
were seeded at a range ofcell numbers, from 0.2 x 105 to 1.2 x 105,
cultured for 5 days and then assayed for MIBG uptake as
described below. A second set of cultures were used for RNA
extraction and RT-PCR as detailed below.
Clonogenic assay
The toxicity of the cisplatin concentrations used was determined
by clonogenic assay. For this, cells were seeded in 25-cm2 flasks at
2.5 x 105 cells per flask. After 2 days, medium was removed and
replaced with fresh medium containing the appropriate concentra-
tion of cisplatin. After 24 h, medium was removed and the cells
were washed three times with phosphate-buffered saline. Fresh
medium was added and the cells were incubated for a further 24 h.
Cells were then trypsinized and counted. For each cisplatin
concentration, three flasks were seeded at 1000 cells per flask.
Flasks were equilibrated with 5% carbon dioxide and then incu-
bated at 37°C. After 14 days, medium was removed and the
colonies were fixed and stained with Carbol Fuschin. Colonies of
more than 50 cells were counted using an automated colony
n2 ofculture dish. counter (Artek Systems).
it experiments in
MIBG uptake studies
Cells were seeded in six-well plates at an initial density of 0.5 x trter expression In 105 cells and cultured for 48 h. Cisplatin was then added at the
appropriate concentration and the cells incubated for 24 h. The
rarget - reference medium was then removed; the cells were washed with phosphate-
ratio buffered saline, and 5 ml of fresh medium was added. Cells were
0.96 assayed for MIBG uptake - before cisplatin exposure, at the point
of cisplatin removal and 24 h after cisplatin removal. MIBG
1.01 incorporation was measured by incubating for 2 h with 7 kBq of
0.82 ['3'I]MIBG. Non-specific uptake was measured in the presence of
0.45 1.5 gM DMI. After incubation, medium was removed, the cells
were washed withphosphate-buffered saline andradioactivity was
0.32 extracted using 2 aliquots of 10% (w/v) trichloroacetic acid. The
0.25 activities of the extracts were then measured in a gamma-well
counter. Specific uptake, expressed as c.p.m 10-5 cells, was calcu-
ty of PCR signals lated by subtracting values obtained in the presence of DMI from
R, reference total uptake.
insporter).
Cisplatin was obtained from David Bull Laboratories (Warwick,
UK). Desmethylimipramine (DMI) and reserpine were purchased
from Sigma (Sigma-Aldrich, Dorset, UK). RNA extraction was
performed using the PUREscript RNA isolation kit, and cDNA
synthesis was carried out using the Clontech 1st-strand cDNA
synthesis kit (both Cambridge Biosciences, Cambridge, UK). PCR
primers were obtained from Oswell (Southhampton, UK). Taq
polymerase for PCR was obtained from Boehringer Mannheim
(Lewes, UK)
Effect of culture density on MIBG uptake and
noradrenaline transporter gene expression
The influence ofcell culture density on the active incorporation of
MIBG was determined using SK-N-BE(2c) cells that had not been
subjected to treatment with cisplatin. Transcription by SK-N-
BE(2c) cells ofthe noradrenaline transporter gene was assessed by
reverse transcription-polymerase chain reaction (RT-PCR). Cells
MIBG release experiments
To determine whether cisplatin treatment affected storage capacity
ofthe neuroblastoma cells, experiments were carried out to inves-
tigate the kinetics of release of MIBG from control and treated
cells. At 48 h after initial cisplatin exposure, cells were incubated
with labelled MIBG as described above. The culture medium was
then removed and changed for drug-free fresh medium or medium
containing 1.5 ,UM DMI. In a second set of cultures, medium was
replaced with drug-free fresh medium or medium containing 2gM
reserpine. At 0, 2, 4 and 6 h after withdrawal of MIBG, the cells
were assayed for MIBG retention. Data were analysed using the
Student's t-test.
RT-PCR analysis of noradrenaline transporter gene
expression
Total RNA was extracted from control- and cisplatin-treated
cultures - before treatment, at the time of cisplatin removal and
24 h aftercisplatin removal. The concentrations oftheRNA samples
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Figure 2 Cytotoxicity of cisplatin to SK-N-BE(2c) cells determined by
clonogenic assay. Note that both scales are logarithmic
were determined by A260 measurements. One microgram of RNA
was reverse transcribed using random hexamer primers, and the
resultant cDNA was PCR amplified using primers specific for the
transporter sequence. The sense primer was 5'-CTGGTGGTGAAG-
GAGCGCAACGGC-3', and the antisense primer was 5'-ATGT-
CATGAATCCCGCTGCTCTCG-3' (Montaldo et al, 1992). This
amplification generated a 590-bp PCR product. Semiquantitation
was achieved by comparison of the target signal with the signal
generated by co-amplification of a reference sequence glyceralde-
hyde-3-phosphate dehydrogenase (GAPDH). The GAPDH primers
were 5'-GCATTGCTGATGATCTTGAGGC-3' (sense) and 5'-
TCGGAGTCAACGGATT'GG-3' (antisense). These generated a
300-bp PCR product. Co-amplification of target and reference
sequences was performed in 10 x synthesis buffer containing
100 mM Tris-HCl, 15 mm magnesium chloride, 500 mm potassium
chloride, pH 8.3 with 10 nmol of dNTPs, 20 pmol of each target
primer, 20 pmol ofeach reference GAPDH primer and 2 units ofTaq
polymerase. Cycling conditions consisted of 1 min denaturation at
94°C, 1 min annealing at 65°C and 1 min extension at 72°C for 35
cycles. The PCR products were separated by electrophoresis through
1.6% (w/v) agarose (Flowgen, Kent, UK). These were densitometri-
cally scanned using Quality One Image Analysis software.
RESULTS
Effect of culture density
Initial experiments were undertaken to monitor the effects of
culture density on MIBG uptake and transporter expression. These
confirmed the previous observations (Montaldo et al, 1992) that at
high culture densities (greater than 0.24 x 105 cells cm-2 which is
equivalent to 2.5 x 105 cells per well) there was a progressive
decline in MIBG accumulation (Figure 1). RT-PCR analysis
confirmed that this reduction in uptake was due to decreased
expression of the gene encoding the noradrenaline transporter
(Table 1). Accordingly, in all cisplatin experiments, cell numbers
in control and treated cultures were kept below this figure. Data
from wells containing more than 2.5 x 105 cells were discarded.
Cisplatin
exposure Day
Figure 3 Effect of cisplatin pretreatment on MIBG uptake in SK-N-BE(2c)
cells. Cells were incubated with cisplatin (CP) for 24 h as indicated. MIBG
uptake was measured before CP treatment (day 0), at CP removal (day 1)
and 24 h later (day 2). X, control; *, 0.02 gM CP; *, 0.2 lM CP; A, 2 gM CP;
*, 20 gM CP. Points represent the means and standard deviations of three
experiments in triplicate. Double asterisks indicate specific uptake
significantly different from control, P<0.01. Triple asterisks indicate specific
uptake significantly different from control, P<0.001
Oh
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Figure 4 RT-PCR analysis of noradrenaline transporter expression in cells
exposed to 20 gM cisplatin. Transporter expression was assayed before CP
exposure (O h), immediately after CP removal (24 h) and 24 h later (48 h). M,
molecular weight markers; C, control; T, treated
Table 2 Semiquantitation of expression of noradrenaline transporter gene in
cisplatin-treated cells.
Concentration of Noradrenaline transporter expression (% of control)
cisplatin (gM)
At 24 h At 48 h
0.02 115±6.2 89±11.2
0.20 120+7.5 94±8.4
2.00 129+7.9 134+9.3
20.00 125 ± 8.2 165+10.6
The values presented are ratios of intensity of target sequence to intensity of
reference sequence. The results are expressed as the per cent of control
values.
Effect of cisplatin on SK-N-BE(2c) survival
Thetoxicity ofarange ofconcentrations ofcisplatin was determined
byclonogenic assay. Figure 2 shows that the toxic effects ofcisplatin
were apparent at concentrations ofthe drug greater than 0.2gM.
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Figure 5 A-D Effect of cisplatin treatment on retention of MIBG in SK-N-BE (2c) cells. Cells were treated with the appropriate concentration of cisplatin for 24
hours. After a further 24 hour incubation cells were assayed for MIBG retention. Cells were loaded with MIBG for 2 hours and then incubated in the presence of
1.5 gim DMI or 2 ,uM reserpine. The amount of MIBG retained was then measured at 2, 4 and 6 hours. Data points represent the means and standard deviations
of 3 experiments in triplicate. -U-: control (- DMI or - reserpine), -*a: control (+ DMI or + reserpine) -E-: CP treated (- DMI or - reserpine), --: CP treated
(+ DMI or + reserpine)
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Figure 6 Possible scheme for neuroblastoma treatment utilising cisplatin stimulation of ['3'1]MIBG in neuroblastoma cells
Effect of cisplatin pretreatment on MIBG uptake
SK-N-BE(2c) cells were incubated with a range of concentrations
of cisplatin for 24 h. The ability of the cells to incorporate MIBG
was then assessed immediately after drug removal and 24 h after
drug removal. The degree of specific uptake was calculated for
each cisplatin concentration and compared with that of control
cultures. Figure 3 shows that cisplatin induced a concentration-
dependent stimulation in active incorporation of MIBG. At the
point of drug removal, values for MIBG uptake after 0.02, 0.2, 2
and 20 gM cisplatin were 95% (not significantly different from
control), 134% (P<0.01), 178% (P<0.001), 232% (P<0.001) of
control values respectively. After a further 24 h, this enhancement
was even more pronounced with uptake values of 171%
(P<0.001), 162% (P<0.001), 355% (P<0.001) and 431%
(P<0.00l) ofcontrols.
Effect of cisplatin pretreatment on expression of the
noradrenaline transporter
Expression of the noradrenaline transporter molecule was exam-
ined in control and treated cells by RT-PCR. The cDNA amplifica-
tion products obtained after exposure of SK-N-BE(2c) cells to 20
gM cisplatin are shown in Figure 4. For each time point and treat-
ment, the ratio oftarget to reference signal intensity was calculated
and expressed as the per cent ofthe control value. These results are
summarized in Table 2. These data demonstrate that cisplatin
induced a dose-dependent stimulation of expression of the trans-
porter molecule. At 0.02 gM and 0.2 gm levels of cisplatin, the
enhanced expression was not maintained after removal ofthe drug.
However at higher concentrations (2.0 and 20 gM), the effect was
prolonged and was in fact greater at 48 h than at 24h after the initi-
ation of exposure to cisplatin. These results indicate that the
cisplatin-induced enhancement of MIBG uptake was due to
increased synthesis of new transporter molecules - as opposed to
increased activity ofexisting molecules.
Effect of cisplatin pretreatment on retention of MIBG
To determine whether cisplatin enhanced the ability of SK-N-
BE(2c) cells to store catecholamines, experiments were carried out
to determine the retention of MIBG. These were performed in the
presence of reserpine (which depletes neurosecretory granules)
and DMI (which inhibits re-uptake of released drug by the trans-
porter). In control- and cisplatin-treated cells, spontaneous release
Sterilisation of cells
surviving earlier
treatment
of MIBG was similar to that in the presence of reserpine. In
contrast, DMI induced a rapid depletion of MIBG from the cells
(Figure 5). These results show that the cisplatin-treated cells main-
tain levels ofMIBG by continual re-uptake ofreleased drug via the
noradrenaline transporter. Cisplatin did not induce the cells to
develop reserpine-sensitive storage granules as no statistically
significant difference in the retention of radiopharmaceutical was
observed in the presence or abscence ofreserpine (P>0.1).
DISCUSSION
It may be possible to improve MIBG-targeted radiotherapy for
neuroblastoma by increasing the capacity of tumour cells for
active uptake or retention of the radiopharmaceutical. Because of
the growing interest in combining MIBG-targeted radiotherapy
with other treatment modalities (Gaze and Wheldon, 1996), it is
important to establish the optimal sequence of administration of
treatments. The present study focused on the effect of cisplatin
pretreatment upon the accumulation and retention of MIBG by
neuroblastoma cells. Cisplatin was selected for study because it is
used effectively in the treatment ofneuroblastoma (Pinkerton et al,
1990; De Bernardi et al, 1992; Pearson et al, 1992) and because it
may act in synergy with radiotherapy (Dewit, 1987).
Our results clearly demonstrate that neuroblastoma cells prein-
cubated with therapeutically relevant doses of cisplatin, which
induced approximately one log cell kill in vitro, more efficiently
concentrated MIBG than untreated controls. The enhanced accu-
mulation of radiopharmaceutical does not appear to be a result
of elevated proficiency of granular storage as the MIBG content
of the cells was unaffected by treatment with 2gM reserpine.
Conversely, desmethylimipramine, atricyclic antidepressant which
is a specific inhibitor of the active uptake of neurotransmitters by
adrenergic neurones, caused the depletion ofMIBG from cisplatin-
treated cells. This suggests that the cisplatin-enhanced MIBG
uptake resulted from an increased capacity to actively accumulate
the drug. This notion is supported by the observation ofa cisplatin-
provoked (dose-dependent) stimulation of the transcription of the
noradrenaline transporter gene. The latter outcome may be a reflec-
tion of the more highly differentiated cellular phenotype which is
inducible by cisplatin (Doi et al, 1995; Kumar and Singh, 1995) or
cisplatin analogues (Maurer et al, 1993).
The mode of cell death induced by cisplatin is complex, dose-
dependent and influenced by cellular phenotype. At supralethal
concentrations of cisplatin (100 gM), rapid apoptotic death
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occurred in a murine leukaemic cell line, whereas lower concen-
trations (1-10 tM) caused G2 arrest followed by slow non-apop-
totic death (Ormerod et al, 1994). Others have shown that, in
human lymphoblastoid cells, DNA damage by cisplatin may result
in p53-mediated apoptosis of cells in G,/S-phase or p53-indepen-
dent apoptosis ofp53 mutant cells in G2/M-phase ofthe cell cycle
(Allday et al, 1995). It has been demonstrated previously that SK-
N-BE(2c) cells respond to cisplatin treatment by undergoingG,/M
blockade and subsequent apoptosis (Piacentini et al, 1993).
Treatments which enhance uptake of MIBG by neuroblastoma
cells in culture include ionizing radiation, interferon-y and phorbol
esters (Smets et al, 1991; Montaldo et al, 1992, 1996). In common
with these agents, cisplatin causes perturbations ofthe DNA which
in turn up-regulate p53 expression. Cisplatin can induce the
expression of p53-dependent genes, such as the CIPI gene,
encoding the cell cycle kinase inhibitor p21 (El-Deiry et al, 1994).
It is possible that cisplatin enhancement of the cellular accumula-
tion of MIBG results from transcriptional transactivation of the
noradrenaline transporter gene via a putative p53 consensus
sequence in the promoter.
In addition to the activation of apoptosis by the formation of
DNA adducts (Cece et al, 1995; Dole et al, 1995) cisplatin may
inhibit the growth ofneuroblastoma cells by virtue ofits capacity to
promote differentiation. Indeed, a range of cytotoxic agents,
including epirubicin and tiazofurin (Rocchi et al, 1987; Pillwein
et al, 1993), and gamma irradiation (Rocchi et al, 1993) have been
shown to induce biochemical as well as morphological evidence of
differentiation of neuroblastoma in vitro. Cisplatin has been
reported to induce neurite outgrowth at concentrations of0.4-13.2
gM (Konings et al, 1994). These doses are within the range of
plasma concentrations achieved during therapy (Ardiet et al, 1989).
In the population ofcells which survived cisplatin treatment, the
relative proportions of cycling cells, quiescent cells, clonogens
and doomed cells are not known. Therefore, the cellular phenotype
(subpopulation) which displayed an increased capacity for active
uptake of MIBG cannot be assigned with certainty. However, a
previous study involving six neuroblastoma cell lines revealed a
strong linear correlation between capacity for active uptake of
MIBG and expression ofthe noradrenaline transporter gene (Mairs
et al, 1994). This suggests that the latter phenomenon may be
partly or wholly responsible for the increased accumulation of
radiopharmaceutical by cisplatin-treated cells and that this charac-
teristic is probably a manifestation of more mature neuroblasts, as
previously demonstrated in neuroblastoma cultures exposed to
maturation-inducing agents (Montaldo et al, 1992).
From a therapeutic perspective, the most important considera-
tion in the use of I3'l-labelled radiopharmaceuticals is maximiza-
tion of beta-particle cross-fire irradiation from targeted regions of
tumour to adjacent malignant cells. In a treatment regimen
involving the delivery of cisplatin followed by ['31I]MIBG, it is
probable that even those cells which are destined to die as a result
of cisplatin administration could contribute to the radiation cross-
fire effect by virtue of their increased uptake of the radiopharma-
ceutical. Therefore, regardless ofthe cellular sub-type responsible
for the increase in MIBG accumulation, the therapeutic outcome
of the enhanced expression ofthe noradrenaline transporter would
be an increase in beta-decay particle energy deposition within
tumour sites.
Recently, cisplatin has been used in combination with
['311]MIBG for the therapy of relapsed neuroblastoma patients
with progressive disease (Mastrangelo et al, 1995). In this
unpromising group, a very impressive response rate of 67% was
obtained. Interestingly, the therapeutic regimen involved two
injections ofcisplatin, administered one week apart, both followed
one day later by injection of ['3'I]MIBG. While extrapolation from
in vitro results to clinical application must be carried out with
great caution, it is tempting to speculate that the exceptionally high
percentage of patients who derived benefit from this particular
combination of treatments may have resulted from cisplatin-
induced enhancement ofthe expression ofthe noradrenaline trans-
porter gene by neuroblastoma cells.
Our investigation raises several important questions of mecha-
nistic and therapeutic significance which must be investigated
using in vivo and in vitro models. What is the relative importance
ofcell cycle redistribution and cellular differentiation to cisplatin-
enhanced uptake of MIBG? Does the effect depend upon whether
the tumour cells are efficient or inefficient accumulators of
MIBG? Are other therapeutically relevant genes overexpressed
following exposure to cisplatin? Would non-target cells also
modulate noradrenaline transporter gene expression after cisplatin
administration? Do chemotherapeutic agents other than cisplatin
elicit responses which are potentially synergistic with targeted
radiotherapy? For example, what would be the effect upon
[1r3I]MIBG uptake of a (cytocidal) priming dose of radiolabelled
or non-radiolabelled MIBG?
It is important to note that the increased accumulation ofMIBG
after chemotherapy, reported in this paper, has been seen to occur
for up to 48 h following treatment; but studies of longer-term
effect, most appropriately using in vivo models, have not yet been
undertaken. Theoretical arguments favouring [113]MIBG as
primary treatment followed by intensive chemotherapy regimens
(Gaze and Wheldon, 1996) remain in place and are not obviated by
these findings over a 2-day period. It is not theoretically optimal
that initial chemotherapy should be of such intensity and duration
as to cause extensive cell kill and tumour regression before
['31I]MIBG treatment is given. However, the present studies do
raise the possibility that initial briefexposure to cisplatin, perhaps
a single treatment, at first presentation could then be followed
by ['311I]MIBG and a more intensive combination to achieve
maximum therapeutic benefit (see Figure 6).
CONCLUSION
This study indicates that a potentially important consequence of
the treatment ofneuroblastoma cells with cisplatin is the improved
capacity for active accumulation of MIBG. Exploitation of this
effect by appropriate scheduling of cisplatin and ['311]MIBG
administration could facilitate augmented tumour cell kill because
ofmaximization ofradiation cross-fire from 'r'I disintegration.
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